Human medicines European public assessment report (EPAR): Bekemv, eculizumab, Date of authorisation: 19/04/2023, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Date of authorisation: 24/05/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): DuoPlavin, clopidogrel,acetylsalicylic acid, Date of authorisation: 14/03/2010, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Enwylma, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

EMA/PASS/0000287665

PSUSA/00010000/202601

Human medicines European public assessment report (EPAR): Zumrad, sasanlimab, Status: Application withdrawn

Annex to agenda of the CHMP meeting 14-17 September 2026

Agenda of the CHMP meeting 14-17 September 2026

Committee for Medicinal Products for Human Use (CHMP): 14-17 September 2026, European Medicines Agency, Amsterdam, the Netherlands, from 14 September 2026 to 17 September 2026